0.0472

5.60% -0.0028

Psyence Biomedical Ltd (PBM)

Overview News Price History Discussions Forecast

Psyence Biomedical Ltd stock is traded at $0.0472, with a volume of 2.20M. It is down -5.60% in the last 24 hours and down -59.17% over the past month. Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Previous Close:

$0.05

Open:

$0.05

24h Volume:

2.20M

Relative Volume:

0.33

Market Cap:

$3.17M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-12.59%

1M Performance:

-59.17%

6M Performance:

-94.44%

1Y Performance:

+0.00%

1-Day Range:

$0.046

$0.05

1-Week Range:

$0.046

$0.058

52-Week Range:

$0.046

$4.31

Psyence Biomedical Ltd Stock (PBM) Company Profile

Name

Psyence Biomedical Ltd

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

PBM's Discussions on Twitter

Compare PBM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PBM	0.0472	3.17M	0	0	0	0.00
VRTX	447.41	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	742.11	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	589.03	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	250.03	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.69	24.49B	3.30B	-501.07M	1.03B	11.54

Psyence Biomedical Ltd Stock (PBM) Latest News

Nov 20, 2024

Psyence Biomedical Secures Extension To Meet Nasdaq Compliance Standards - Benzinga

Nov 20, 2024

Psyence Biomedical to consolidate shares in bid to keep Nasdaq listing - Green Market Report

Nov 20, 2024

Psyence Biomedical gets extension to show compliance with Nasdaq’s listing rules - MSN

Nov 20, 2024

Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing - The Manila Times

Nov 20, 2024

Psyence Biomed granted Nasdaq listing extension - Investing.com

Nov 20, 2024

Psyence Biomedical Announces Favorable Result Of Nasdaq Listing Qualifications Hearing - XM

Nov 20, 2024

Psyence Biomedical Secures Nasdaq Extension, Plans 1-for-75 Share Consolidation | PBM Stock News - StockTitan

Nov 20, 2024

Psyence Biomedical fell on 75-to-1 share consolidation and Nasdaq delisting notice - MSN

Nov 20, 2024

Nov 19, 2024

Psyence Biomed announces share consolidation date - Investing.com India

Nov 19, 2024

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation - The Manila Times

Nov 19, 2024

Psyence Biomedical Implements 1-for-75 Share Consolidation to Meet Nasdaq Requirements | PBM Stock News - StockTitan

Nov 19, 2024

Psyence Biomed announces share consolidation date By Investing.com - Investing.com Canada

Nov 19, 2024

Nov 12, 2024

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq - The Manila Times

Nov 12, 2024

Psyence Biomedical Shareholders Approve 75:1 Stock Split Amid Nasdaq Compliance Challenge | PBM Stock News - StockTitan

Nov 12, 2024

Psyence Biomedical Announces Results from Annual and - GlobeNewswire

Nov 12, 2024

Oct 31, 2024

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs - GlobeNewswire

Oct 31, 2024

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs - Yahoo Finance

Oct 31, 2024

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs - The Manila Times

Oct 31, 2024

Oct 30, 2024

Where Do Analysts See Psyence Biomedical Ltd. (NASDAQ: PBM) Heading? - Stocks Register

Oct 30, 2024

Oct 26, 2024

Bullish Prospects For Psyence Biomedical Ltd. (NASDAQ: PBM) Shares In 2024 - Stocks Register

Oct 26, 2024

Oct 25, 2024

Natural Gas LDay (F) (HHM19) Quote - The Globe and Mail

Oct 25, 2024

Psyence Biomed adds Australian site for psilocybin trial - Investing.com

Oct 25, 2024

Oct 24, 2024

Psyence Biomed adds Australian site for psilocybin trial By Investing.com - Investing.com South Africa

Oct 24, 2024

Psyence Biomed Announces Recruitment of Second Clinical - GlobeNewswire

Oct 24, 2024

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care - StockTitan

Oct 24, 2024

Oct 23, 2024

Psyence Biomedical Sets Annual General Meeting for November 12 - Investing.com

Oct 23, 2024

Psyence Biomedical Plans Key Shareholder Meeting - TipRanks

Oct 23, 2024

Psyence Biomedical Sets Annual General Meeting for November 12 By Investing.com - Investing.com UK

Oct 23, 2024

Oct 17, 2024

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development - The Manila Times

Oct 17, 2024

Oct 14, 2024